# Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM

> **NCT04891809** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Arbeitsgemeinschaft medikamentoese Tumortherapie** · enrollment: 198 (estimated)

## Conditions studied

- Newly Diagnosed Multiple Myeloma

## Interventions

- **DRUG:** Isatuximab-Irfc 20 MG/ML [Sarclisa]
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone Oral

## Key facts

- **NCT ID:** NCT04891809
- **Lead sponsor:** Arbeitsgemeinschaft medikamentoese Tumortherapie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-20
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 198 (ESTIMATED)
- **Last updated:** 2025-04-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04891809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04891809, "Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04891809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*